PATIENT TESTIMONIES: more stories from NEN patients

Neuroendocrine neoplasms (NENs) and metastatic castration-resistant prostate cancer (mCRPC) are currently being treated with radioligand therapies (RLTs), a novel method of cancer treatment. People with breast, kidney, colon, or pancreatic cancer, have enormous potential to also be treated with this innovative therapy.

One of SPARC-Europe's objectives is to keep promoting the advantages of this treatment by widely disseminating stories about patients’ experiences, as patient education, awareness, and understanding of the treatment all remain barriers to RLT acceptance. Over the next two weeks, the Alliance will be releasing five new testimonials for their series of patient testimony videos, following the stories unveiled earlier this year.

The videos have been created in collaboration with the patient organisation International Neuroendocrine Cancer Alliance (INCA) and Steering Committee Member Dr. Ken Herrmann, featuring the testimonials of five neuroendocrine neoplasms patients: Barbara from Italy, Tomas from Sweden, Martin from Bulgaria, Joel from France and Volker from Germany.

Throughout their stories, patients outline their diagnoses and treatment pathway, their experience with RLT and the future they foresee for the treatment and NEN patients, wishing to shed light to policymakers and stakeholders on this therapy known for improving patients’ quality of life.

In the third of the five stories, Tomas from Sweden tells about his journey from diagnosis of a small intestinal neuroendocrine tumor to the treatment by radioligand therapy in Sweden.  In his statement, Tomas shows gratitude for his country’s efficient healthcare system, specialists close to this home who can perform RLT, and how he was well-informed about the treatment process. He hopes to see radioligand therapy treatment more widely available to NEN patients across the EU. Watch the video to learn more!

Stay tuned to also learn more about Joel and Volker and hear their stories!